Afsaneh Lavasanifar, Curriculum Vitea 15 A. PERSONAL INFORMATION
Name: Afsaneh Lavasanifar University Address: 2142F Katz Group/Rexall Center for Pharmacy and Health Research, University of Alberta, Edmonton, AB, Canada T6G 2E1
Tel: (780) 492-2742 Fax: (780) 492-1217 E-mail: [email protected] Internet: http://www.pharmacy.ualberta.ca/Lavasanifar_lab/ Nationality: Canadian/Iranian Language: English, Farsi
B. UNIVERSITY EDUCATION
09/1996 - 09/2001 Ph.D. Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB.
01/1983 – 06/1988 Pharm. D, Pharmacy, Tehran University of Medical Sciences, Iran.
C. PROFESSIONAL EXPERIENCE
07/2011-Present Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB
05/2009 - Present 07/2005–06/2011
Adjunct Professor, Department of Chemical and Material Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB Associate Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB
11/2001-06/2005 Assistant Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB
09/1997-09/2001 Teaching Assistant, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB
05/1994-05/1996 Formulation Consultant, Iran Daru (Pharmaceutical company), Iran
03/1992-05/1996 Lecturer in Pharmaceutics, Dr. Beheshti University of Medical Sciences, Tehran, Iran
I. BACKGROUND INFORMATION
LAVASANIFAR, AFSANEH Nov 2013
2
02/1989-02/1992 Research Scientist, Food & Drug Organization, Tehran, Iran
D. AWARDS AND HONORS 2013 TEC Edmonton, Innovation makes sense.
2009 2009 2007 2007 2006 2000
Sanofi-aventis/AFPC New Investigator Research Award; Presented by the Association of the Faculties of Pharmacy of Canada, annual meeting, Halifax, June 2009. Top 3 most cited paper in Journal of Pharmaceutical Sciences.
GlaxoSmithKline Early Career Award, Presented by the Canadian Society for Pharmaceutical Sciences (CSPS) in their 10th annual symposium in Montreal, Quebec. Top 10 most cited paper in Journal of Controlled Release in 2005. Journal of Controlled Release, Most cited paper in 2005 award. Wu Hong Poster Prize for visual presentation display at the Research Day, University of Alberta, AB, Canada.
09/2000-09/2001 Mike Wolowyk Graduate Scholarship,
2000 Association of Faculties of Pharmacy of Canada Award, University of Saskatoon, SK, Canada.
1999 American Association of Pharmaceutical Scientists, Pharmaceutics and Drug Delivery Section Annual Meeting Travelship Award, Neworleans, LA, USA.
1999 Wu Hong Poster Prize for visual presentation display at the Research Day, University of Alberta, AB, Canada.
1998 Mary Louse Imrie Graduate Students Award for poster presentation at the Annual Meeting of the American Association of Pharmaceutical Scientists in San Francisco, University of Alberta, AB, Canada.
E. PROFESSIONAL ORGANIZATION MEMBERSHIP - Canadian Society of Pharmaceutical Scientists (CSPS)
- Association of the faculties of Pharmacy in Canada (AFPC)
- American Society of Pharmaceutical Scientist (AAPS)
- Controlled Release Society (CRS)
LAVASANIFAR, AFSANEH Nov 2013
3
A. RESEARCH INTERSTS
1. Design and development of nanotechnology products for improving response to cancer chemotherapy. Research on this topic is pursued in two avenues:
a. Development of polymeric nano-carriers for the targeted delivery of anticancer drugs. The mission of this research program is to develop innovative pharmaceuticals (with particular focus on nano-medicine) that offer bio-available, less toxic, and more effective alternativeness to current drugs in combating hard-to-treat and resistant cancers. Particular attention is paid to the development of engineered carriers that provide specific delivery of anti-cancer drugs to cellular and intracellular targets. Collaborations on this line of research are established with Dr Lai (Cross Cancer Institute), Dr Kaur and Dr Seubert (Faculty of Pharmacy). Different elements of this project have been funded by NSERC and CIHR.
b. Development of polymer based nano-carriers for the tumor targeted delivery of modulators of drug resistant. It is the objective of this research to either silence the expression or inhibit the function of oncoproteins responsible for resistance to therapy in several tumors. Collaborations are in place with Dr Uludag (Chemical and Material Engineering), Dr Lai (Cross Cancer Institute) and Dr Brocks (Faculty of Pharmacy) on this research. The research is currently funded by a collaborative research grant from NSERC/CIHR.
2. Development of new biodegradable block copolymers for mucosal and regional delivery.
This project is seeking development of a new family of biodegradable polymeric micellar delivery systems and thermo- and pH responsive hydrogels for the solubilization of poorly water soluble drugs and/or depot drug release. Collaborations with Dr Choi (Chemical and Material Engineering), Dr Unswarth (NINT and Chemical Material Engineering) and Dr Sundararaj (Chemical and Material Engineering) are pursued on this project. Different aspects of this project have been funded by AHFMR and NSERC.
3. Development of nano-delivery systems for cancer immunotherapy and immunomonitoring-
The nanoparticle delivery of therapeutic cancer vaccines to dendritic cells (DCs) for the modulation of T cell mediated immune responses constitutes is an alternative method that (in combination with targeted chemotherapy) has the potential to make an extraordinary world-wide advancement in cancer eradication. A major barrier to cancer immunotherapy is cancer-induced immune tolerance. The objective of this research is to exploit development of nanoparticulate based cancer vaccines that can provide a plat form for co-delivery of cancer antigens and adjuvants to DCs boosting immune response against cancer associated/specific antigens. A second objective under this project will seek design of tumor or DC targeted nano-delivery systems for overcoming immunotolerance against cancer vaccines. We also have an interest in the development MRI and PET nano-probes for DC and T-cell imaging in the context of cancer immunotherapy.
II. RESERCH AND SCHOLARY ACTIVITIES
LAVASANIFAR, AFSANEH Nov 2013
4
B. RESEARCH GRANTS a. Received:
Title of the grant Source Role Total amount
Period of support
Nanodelivery Systems for Modulation of Chemotherapy Response in Invasive and Metastatic Breast Cancer
CIHR PI 100,000 10/2014-09/2015
Novel Nanoparticulate STAT3 Inhibitors for Treating Multiple Myeloma
AIHS Co-PI $750,000 04/2014-03/2017
Chemical tailoring of micelle-forming poly(ethylene oxide)-b-poly ester copolymers for drug delivery
NSERC PI $125,000 04/2014-03/2019
Chemical tailoring of micelle-forming poly(ethylene oxide)-b-poly ester copolymers for drug delivery
NSERC PI $29,000 04/2013-03/2014
A Digital PCR for Biomedical Engineering Application
NSERC (RTI) Co-PI $79,600 04/2013-04/2014
Tumor targeted polymeric nanocarriers for oncogene silencing therapy of metastatic breast cancer
CIHR1/ACF2 PI $ 100,000 10/2012-09/2013
Fluorescence lifetime imaging and fluorescence polarization for elucidation of molecular level events: peptide self-assembly, NP disassembly in cells, and phage binding.
NSERC (RTI) Co-PI 86,288 09/2012-09/2014
An Inverse Gas Chromatographic System for the Characterization of Biopolymers
NSERC (RTI) Co-PI 63,000 09/2012-09/2014
siRNA Based Molecular Therapy for Reversal of Drug Resistance in Leukemia
Alberta Cancer Foundation
Co-PI $ 300,000 09/2011-09/2013
Nano-delivery systems for cancer immunotherapy: Modulation of the anticancer immunity at the induction and effector phases
CIHR1/ACF2 PI $ 100,000 10/2011-04/2013
Ligand Guided Polymeric Nanocarriers for tumor targeted drug and oncogene silencing therapy
CIHR1/ACF2 PI $ 100,000 04/2011-04/2012
CFI3 PI $ 377,613 09/2011-09/2012 Facility to Support the Bench-to-bedside Development of Targeted
AET4 PI $ 377,613 09/2011-09/2012
LAVASANIFAR, AFSANEH Nov 2013
5
Drugs and Drug Delivery Systems for Improved Therapeutic Performance Application of nanotechnology in delivering targeted anti-cancer therapy
ACF2 Co-PI $ 300,000 05/2010-04/2012
Differential scanning calorimetry for the development of new pharmaceutical with improved performance
NSERC5 PI $ 73,500 04/2010-04/2011
Development of targeted nano-carriers for the delivery of RNAi therapeutics
AET4 PI $ 50,000 09/2010-02 /2011
A New Approach for Sensitization of Chemoresistant Cancers to Drug Therapy
CIHR1/NSERC5
Co-PI $ 100,000 05/2009-05/2010
Chemical tailoring of micelle-forming poly(ethylene oxide)-b-poly ester copolymers for drug delivery
NSERC5 PI 120,300 05/2008-04/2013
Evaluation of current stability of Thioguanine suspension
Capital Health PI $ 6,981 07/2008-12/2008
Tumor Targeted nano-delivery systems for improving response to chemotherapy in cancer
CIHR1 PI $ 149,452 09/2008-04/2011
Nano-delivery systems for cancer immunotherapy: Modulation of the anticancer immunity at the induction and effector phases
CIHR1 PI* $ 540,617 01/2007-09/2011
Beckman Coulter Cell Lab Quanta SC Flow Cytometer
AHFMR6 Co-PI $ 90,000 04/2007-04/2008
Biodegradable block copolymers as injectable hydrogels for depot drug delivery
AHFMR6 PI $ 15,000 09/2007-12/2007
Ligand guided polymeric nano-carriers for targeted drug and vaccine delivery in cancer
NSERC5 PI * $ 649,707 09/2006-09/2009
Nuclear Magnetic Resonance (NMR) Facility Operator Salary/Maintenance Support and 400 MHz NMR Spectrometer System
CIHR1 Co-PI $ 495,665 04/2006-03/2011
Assessing the stability of 6-Mercaptopurine suspensions
Novopharm PI $ 7,000 01/2006-01/2012
Polymer based nanocarriers for the solubilization and controlled delivery of hydrophobic drugs
AHFMR6 PI $ 35,000 03/2005-03/2006
Molecular Biopharmaceutics, Drug CFI3-IOF Co-PI $ 50,092 08/2004-08/2010
LAVASANIFAR, AFSANEH Nov 2013
6
Metabolism and pharmacokinetics Facility Molecular Biopharmaceutics, Drug Metabolism and pharmacokinetics Facility
CFI3 Co-PI $ 492,436 06/2003-06/2004
Waters Micromass LC Mass spectrometrySystem
AHFMR6 Co-PI $ 158,254 06/2003-06/2004
Chemical tailoring of micelle-forming poly(ethylene oxide)-b-poly ester copolymers for drug delivery
NSERC5 PI $ 125,000 05/2003-04/2008
University of Alberta Startup fund University of Alberta
PI $ 50,000 01/2002-03/2006
1Canadain Institute of Health Research (CIHR) 2 Alberta Cancer Foundation (ACF) 3 Canadian Foundation for Innovation (CFI) 4Alberta Advanced Education and Technology (AET) 5 Natural Science and Engineering Research Council of Canada (NSERC) 6Alberta Heritage Foundation for Medical Research (AHFMR) * The original PI of this grant was Dr John Samuel. I took the role of PI in this grant after his passing in April 2007. C. RESEARCH COMMUNITY a. Editorial board
1. Section Editor of Journal of Pharmacy and Pharmaceutical Sciences 2. Open Nanomedicine, Bentham Science Publishers Ltd, the Netherlands 3. Materials Sciences and Applications, Bentham Science Publishers Ltd, the Netherlands 4. Iranian Polymer Journal, Tehran, Iran.
b. Reviewer for grants
1. National Institute of Health (NIH) ad hoc member in the GDD panel, October 2012, June 2013, Feb 2014.
2. Canadian Institute of Health Research (CIHR), Terry FOX CIHR team grant, May 2011.
3. Quebec Consortium for drug delivery, Internal reviewer, 2012.
4. National Cancer Institute of Canada (NCIC). Panel G1 (Experimental Therapeutics, Medicinal Chemistry and Drug Development) February 2009, Committee member.
5. Canadian Institute of Health Research (CIHR). Pharmaceutical Sciences’ committee member, 2007, 2008, 2009, 2010, 2014.
LAVASANIFAR, AFSANEH Nov 2013
7
6. National Science and Engineering Research Council of Canada (NSERC). External reviewer.
7. Canadian Foundation for Innovation (CFI). External Reviewer.
8. The Wellcome Trust, London. External Reviewer.
9. Saskatchewan Health Research Foundation. External Reviewer.
10. Natural Resources and Applied Sciences (NRAS), Province of British Columbia, External Reviewer.
11. The Danish Council for Independent Research | Natural Sciences, External Reviewer, 2011
c. Review for Journals 1. Pharmaceutical Research
2. Journal of Pharmaceutical Sciences
3. International Journal of Pharmaceutics
4. Biomaterials
5. Biomacromolecules
6. Journal of Pharmacy and Pharmaceutical Sciences
7. Journal of Controlled Release
8. Advanced drug delivery reviews
9. Journal of Biomedical material Research
10. Cancer Chemotherapy and Pharmacology
11. European Journal of Pharmaceutics and Biopharmacutics
12. Macromolecules
13. Molecular pharmaceutics
14. Macromolecular Bioscience
15. Macromolecular rapid communications
16. Progress in Polymer Science
17. AAPS Journal
18. Journal of Vaccum Science and Technology B
19. Daru
20. Journal of Drug Targeting
21. Open Nanomedicine
22. Applied radiation and isotopes
23. Nanomedicine
LAVASANIFAR, AFSANEH Nov 2013
8
24. Polymeric drug delivery: Science and application
25. ACS Nano
26. Journal of drug delivery
27. Journal of biomaterial science, polymer edition
28. Material Science and Engineering C
29. Acta Biomaterialia
30. Pharmaceutical Development and Technology
31. Drug Delivery
32. Chemistry of Materials
33. Molecules
D. PUBLICATIONS a. Published/In Press Refereed Papers * Corresponding author
1. Basak Sahin; Jeremy Fife; Manoj Parmar; Juliana Valencia-Serna; Hilal Gul-Uludag; Xiaoyan Jiang; Afsaneh Lavasanifar; Michael Weinfeld; Hasan Uludag. “siRNA Therapy in Cutaneous T-cell Lymphoma Cells Using Non-Viral (Polymeric) Carriers” Biomaterials, In Press.
2. Soheila Honary, Afsaneh Lavasanifar “The Effect of Self-assembly Conditions on the Size of Di- and Triblock Copolymer Micelles: Solicitation from Response Surface Methodology” Pharmaceutical Development and Technology, In Press.
3. J Emami; M Rezazadeh; M Rostami, F Hasanzadeh; A. Emami, A Mostafavi; M Minaiyan; A Lavasanifar Co-delivery of paclitaxel and a-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy” Drug Development and Industrial Pharmacy, In Press. Available online.
4. Haddadi, Azita; Hamdy, Samar; Ghotbi, Zahra; Samuel, John; Lavasanifar, Afsaneh “Immunoadjuvant Activity of Nanoparticles Surface Modified with Mannan" Nanotechnology, In Press.
5. M, Shahin, N Safaei Nikouei and A Lavasanifar* (2014) “Polymeric micelles for pH responsive delivery of cisplatin to breast tumor cells” Journal of Drug Targeting, 22(7):629-37.
6. Q Zhang, M R Vakili , X-F Li, A Lavasanifar*, X. C Le (2014) “Polymeric Micelles for GSH Triggered Delivery of Arsenic Trioxide Derivatives to Cancer Cells” Biomaterials, 35(25)7088-100.
7. Han M, Vakili MR, Soleymani Abyaneh H. Molavi L and LavasanifarA, Mitochondrial delivery of doxorubicin via TPP modification for the reversal of drug resistance in MDA-MB-435/DOX cells. Molecular Pharmaceutics, In Press.
LAVASANIFAR, AFSANEH Nov 2013
9
8. Hyunah Cho, Clifford S. Cho, Guilherme L. Indig, Afsaneh Lavasanifar, Mohammad Reza Vakili and Glen S. Kwon (2014) “Polymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidance. " PlosOne, 9(2)e89968.
9. Falamarzian A, Aliabadi HM, Molavi O, Seubert JM, Lai R, Uludag H, Lavasanifar A
"Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy" Journal of Biomedical Material Research A, In Press.
10. Hoda Soleymani, Mohammad Reza Vakili, Afsaneh Lavasanifar* (2014) “The Effect of
Polymerization Method in Stereo-active Block Copolymers on the Stability of Polymeric Micelles and their Drug Release Profile” Pharmaceutical Research, 31(6)1485-500.
11. Haeri A, Sadeghian S, Rabbani S, Anvari MS, Lavasanifar A, Amini M, Dadashzadeh S.
(2013) “Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: A comparison of phospholipid micelles and liposomes” International Journal of Pharmaceutics, 455 (1-2) 320-30.
12. Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan IH, Lavasanifar A* and
Lai R* (2013) “Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against ALK+ALCL” Biomaterials, 34(34) 8718-25.
13. Shahin M, Soudy R, Aliabadi HM, Kneteman, N, Kaur K, Lavasanifar A. (2013)
“Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity” Biomaterials, 34(16) 4089-97. (The 2013 winner of the GattefosséCanada CSPS award in Lipid based drug delivery)
14. Binkhathlan, Z., Lavasanifar A* (2013) “P-glycoprotein inhibition as a therapeutic
approach for overcoming multidrug resistance in cancer: current status and future perspectives” Current Cancer Drug Targets, 13:326-346.
15. Mathews AS, Ahmed S, Shahin, M, Lavasanifar A, Kaur K*, (2013) “Peptide Modified
Polymeric Micelles Specific for Breast Cancer Cells” Bioconjugate Chemistry, 24(4):560-70.
16. Abbasi M, Lavasanifar A, Uludağ H (2013) “Recent Attempts at RNAi Mediated P-
glycoprotein Down-Regulation for Reversal of Multidrug Resistance in Cancer” Medicinal Research Reviews, 33(1)33-53.
17. Shahin M, Soudy R, Kaur K, Haitham El-Sikhry1, John M. Seubert, Lavasanifar A (2013)
“Engineered Peptides for the Development of Actively Tumor Targeted Liposomal Carriers of Doxorubicin” Cancer Letters, 334(2):284-92.
18. Xiong XB, Binkhathlan, Z., Molavi O, Lavasanifar A* (2012) “Amphiphilic block
copolymers: preparation and application in nanodrug and gene delivery” Acta
LAVASANIFAR, AFSANEH Nov 2013
10
Biomarterilia, 8(6):2017-33. (The top 25 most downloaded articles between April and June in Acta Biomaterialia).
19. Binkhathlan Z, Brocks DR, Shayeganpour A, Lavasanifar A* (2012) “Encapsulation of P-
glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin.” European Journal of Pharmaceutics and Biopharmaceutics, 81(1):142-8.
20. Falamarzian A., Xiong X.B., Uludag, H and Lavasanifar A, (2012) “Polymeric micelles
for targeted siRNA delivery” Journal of Drug Delivery Science and Technology, 22 (1) 43-54.
21. Binkhathlan Z, Elhasi S, Brocks DR, Lavasaniar A* (2012) “Characterization of the self-
assembly of poly(ethylene oxide)-poly(a-benzyl-e-carboxylate caprolactone) for the solubilization and in vivo delivery of valspodar” Current Drug Delivery, 9(2):164-71.
22. Soudy R, Gill A, Sprules T, Lavasanifar A, Kaur K*, (2011) Proteolitically Stable Cancer
Targeting Peptides with High Affinity for Breast Cancer Cells, Journal of Medicinal Chemistry, 54(21)7523-34.
23. Xiong XB, Lavasanifar A* (2011) “Traceable multifunctional polymeric micelles for co-
delivery of mdr1 siRNA and doxorubicin” ACS Nano, 28;5(6):5202-13. ((Top 20 most downloaded articles between April and June in ACS Nano)
24. Xiong XB, Falamarzian A, Garg S, Lavasanifar A* (2011) “Engineering of amphiphilic
block copolymers for polymeric micellar drug and gene delivery” Journal of Controlled Release,155(2):248-61.
25. Sung B, Prasad S, Yadav VR, Lavasanifar A, Aggarwal B.B* (2011), “Cancer and Diet:
how they are related?” Free Radical Research, 45(8):864-79.
26. Safaiee Nekoie N, Lavasanifar A (2011) “Characterization of the thermo- and pH-responsive assembly of triblock copolymers based on poly(ethylene glycol) and functionalized poly(ε-caprolactone)” Acta Biomaterilia,7(10) 3708-18.
27. Abbasi M., Aliabadi HM, Moase E, Lavasanifar A and Uludag H. (2011) “siRNA
Mediated Down-Regulation of P-glycoprotein in a Xenograft Tumor Model in NOD-SCID Mice” Pharmaceutical Research, 28(10) 2516-29.
28. Hamdy S, Haddadi A, Shayeganpour A., Samuel J, Lavasanifar A (2011) “Activation of
antigen specific T cell responses by mannan-decorated PLGA nanoparticles” Pharmaceutical Research, 28(9) 2288-301.
29. Shahin M, Ahmad S, Kaur K, Lavasanifar A (2011) “Decoration of polymeric micelles
with cancer specific peptides for active targeting of paclitaxel” Biomaterials,
LAVASANIFAR, AFSANEH Nov 2013
11
32(22):5123-33. (Winner of a publication award from Canadian Institute of Health Research/Institute of Cancer Research).
30. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi AOS, Uludag H, Lavasanifar A
(2011) “Down-Modulation of STAT3 in B16 Melanoma by siRNA Induces Bystander Immune Response: an in vitro and in vivo Study” Translational Oncology, 4(3):178-88.
31. Hamdy S, Haddadi A, Shayeganpour A, Aliabadi HM, Lavasanifar A (2011)“The
immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies” AAPS Journal, 13(2):159-68.
32. Bahadur RKC, Landry B, Aliabadi HM, Lavasanifar A, Uludağ H (2011) “Lipid-
Substitution on Low Molecular Weight Polyethylenimine Leads to Effective Assembly of Plasmid DNA and Transgene Expression, Acta Biomaterialia, 7(5):2209-17.
33. Hamdy S, Haddadi A, Hung RW, Samuel J, Lavasanifar A (2011) “Targeting dendritic
cells with nano-particulate PLGA cancer vaccine formulations” Advanced Drug delivery Reviews, 63(10-11)943-55.
34. Hamdy S, Haddadi A, Ghotbi Z, Hung RW, Lavasanifar A (2011) “Targeted Particles for
Cancer Immunotherapy” Current Drug Delivery, 8(3)261-73.
35. Hung RW, Hamdy S, Haddadi A, Ghotbi Z, Lavasanifar A (2011) “Targeted particles for the imaging of anti-cancer immune response” Current Drug Delivery, 8(3)274-81.
36. Garg S, Xiong XB, Lu C, Lavasanifar A (2011) “Application of click chemistry for the
Preparation of Core Crosslinked Polymeric Micelles Based on Poly(ethylene oxide)-poly(ε-caprolactone)” Macromolecules, 44(7)2058-66.
37. Aliabadi, HM, Romanick M, Somayaji V, Mahdipoor P, Lavasanifar A* (2011)“Evaluation of the Stability of compounded Thioguanine suspension” American Journal of Health-System Pharmacy, 15;68(10):900-8.
38. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi S, Uludag H, Lavasanifar A.
(2010) “STAT3 Silencing in Dendritic Cells by siRNA Polyplexes Encapsulated in PLGA Nanoparticles for the Modulation of Anticancer Immune Response” Molecular Pharmaceutics,7(5)1643-1654.
39. Ahmed S, Mathews AS, Byeon N, Lavasanifar A, Kaur K*. (2010) “Peptide arrays for
screening cancer specific peptides” Analytical Chemistry, 82(18):7533-41.
40. Falamarzian A, Lavasanifar A* (2010) “Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(caprolactone) based nano-carriers for the solubilization and delivery of Amphotericin B” Colloids & Surfaces B:Biointerfaces, 81(1)313-20.
LAVASANIFAR, AFSANEH Nov 2013
12
41. Van Guggenberg E, Shahhosseini S, Koslowsky S, Lavasanifar A, Murray D, Mercer J* (2010) “In vitro characterization of two novel biodegradable vectors for the delivery of radiolabelled oligonucleotides” Cancer Biotherapy & Radiopharmaceuticals, 25(6) 723-731.
42. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A* (2011) “Active
targeting of dendritic cells with mannan-decorated PLGA nanoparticles” Journal of Drug Targeting, 19(4)281-292.
43. Xiong XB, Uludag H and Lavasanifar A* (2010) “Virus-mimetic polymeric micelles for
targeted siRNA delivery Biomaterials, 31(22)5886-93.
44. Binkhathlan Z, Hamdy D, Brocks DR, Lavasanifar A* (2010) “Development of a Polymeric Micellar Formulation for Valspodar and Assessment of its Pharmacokinetics in Rat” European Journal of Pharmaceutics and Biopharmaceutics, 75(2)90-5.
45. Abbasi M., Lavasanifar A., Berthiaume L, Weinfeld M and Uludağ H* (2010) “Cationic
polymer mediated small interfereing RNA delivery for permeability glycoprotein down-regulation in tumor cells” Cancer, 116(23)5544-5554.
46. Incani, V., Lin X., Lavasanifar A., Uludag H*. (2010) “Lipid and hydrophobic
modification of cationic carriers on route to superior gene vectors” Soft Matter, 6(10) 2124-2138
47. Alshamsan A, Hamdy S, Das S, Lavasanifar A, Samuel J, El-Kadi AO* (2010)
“Validation of Bone Marrow Derived Dendritic Cells as an Appropriate Model to Study Tumor-Mediated Suppression of DC Maturation through STAT3 Hyperactivation” Journal of Pharmacy and Pharmaceutical Science, 13 (1) 21-6.
48. Falamarzian A, Lavasanifar A* (2010) “Chemical modification of hydrophobic block in
poly(ethylene oxide) poly(caprolactone) based nano-carriers: Effect on the solubilization and hemolytic activity of Amphotericin B" Macromolecular Bioscience, 10(6)648-56.
49. Shahin M, Lavasanifar A* (2010) “Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery” International Journal of Pharmaceutics. 389(1-2):213-222.
50. Patal SK, Lavasanifar A, Choi P* (2010) “Molecular dynamics study of the encapsulation
capability of a block copolymer containing three PCL blocks connected to one end of a PEO block for two classes of hydrophobic drugs with different spatial distributions of hydrogen bond donors and acceptors” Biomaterials, 31(7):1780-6.
51. Alshamsan A, Hamdy S, Samuel J, El-Kadi, O.S. Lavasanifar A*, Uludag H* (2010)
“The Induction of Tumor Apoptosis in B16 Melanoma following STAT3 siRNA Delivery with a Lipid-Substituted Polyethylenimine” Biomaterials, 31(6):1420-8. (The 2010 winner of the Gattefosse Canada / CSPS Research Award in lipid based drug delivery)
LAVASANIFAR, AFSANEH Nov 2013
13
52. Molavi O, Mahmud A, Hamdy S, Hung R, Lai R, Samuel J, Lavasanifar A* (2010)
“Development of a poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticle formulation of STAT3 inhibitor JSI-124: Implication for cancer immunotherapy” Molecular Pharmaceutics, 7(2)364-74. (Cited by national Cancer Institute website, http://nano.cancer.gov/action/news/2010/feb/nanotech_news_2010-02-18d.asp)
53. Xiong XB, Ma Z, Lai R, Lavasanifar A* (2010) “The Therapeutic Response to
Multifunctional Polymeric Nano-Conjugates in the Targeted Cellular and Subcellular Delivery of Doxorubicin” Biomaterials, 31(4):757-68.
54. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A* (2010) “Pharmacokinetics of
PSC 833 (Valspodar) in A Cremophor EL-Based Formulation in Rat” Xenobiotica, 40(1):55-61.
55. Patal SK, Lavasanifar A, Choi P* (2010) “Prediction of the solubility of cucurbitacin
drugs in self associating poly(ethylene oxide)-b-poly( -benzyl carboxylate -caprolactone) block copolymer with different tactiticities using molecular dynamics simulation” Biomaterials, 31(2):345-57.
56. Kanduru S, Lavasanifar A, Brocks DR* (2010) “An analytical method for cyclosporine
using liquid chromatography-mass spectrometry” Biomedical Chromatography, 24(2):148-53.
57. Patal SK, Lavasanifar A, Choi P* (2009) "Roles of Non-polar and Polar Intermolecular
Interactions in the Improvement of the Drug Loading Capacity of PEO-b-PCL with Increasing PCL Content for two Hydrophobic Cucurbitacin Drugs" Biomacromolecules, 10(9):2584-91.
58. Incani V, Lin X, Lavasanifar A, Uludag H* (2009) “Relationship between the extent of
lipid substitution on Poly(L-Lysine) and DNA delivery efficiency” ACS Applied Materials & Interfaces, 1(4) 841-848.
59. Mahmud A, Patal SK, Molavi O, Choi P, Samuel J, Lavasanifar A* (2009) “Self
associating poly(ethylene oxide)-b-poly(ε-caprolactone) block copolymers with pendent cholesterol groups for the solubilization and delivery of STAT-3 inhibitor Cucurbitacin I” Biomacromolecules, 10 (3), 471–478.
60. Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludag H* (2009)
“Formulation and Delivery of siRNA by Oleic Acid and Stearic Acid Modified Polyethylenimine” Molecular Pharmaceutics, 2;6(1):121-133.
61. Xiong XB, Uludag H, Lavasanifar A* (2009) “Biodegradable amphiphilic poly(ethylene
oxide)-block-polyesters with grafted polyamines as supramolecular nanocarrier for efficient siRNA delivery” Biomaterials, 30(2):242-53. Top 25 hottest articles between Oct. and Dec. 2008 in Biomaterials
LAVASANIFAR, AFSANEH Nov 2013
14
62. Molavi O, Ma Z, Hamdy S, Samuel J, Lavasanifar A* (2009) “Immunomodulatory and
anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124” Immunopharmacology and immunotoxicology, 16:1-14.
63. Patal SK, Lavasanifar A, Choi P* (2008) “Application of Molecular Dynamics
Simulation for predicting the solubilization of water insoluble drugs by self associating poly(ethylene oxide)-b-poly(ε−caprolactone) block copolymers” Biomacromolecules, 9(11):3014-23.
64. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A* (2008) “Disposition of Drugs in
Block Copolymer Micelle Delivery Systems: from Discovery to Recovery” Clinical Pharmacokinetics, 47(10):619-34.
65. Ma Z, Molavi O, Haddadi A, Lai R, Gossage R A., Lavasanifar A* (2008)“Resveratrol
analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol” Cancer Chemotherapy and Pharmacology, 63(1):27-35.
66. Xiong XB, Uludag H, Lavasanifar A* (2008) “Multifunctional polymeric micelles for
enhanced intracellular delivery of doxorubicin to metastatic cancer cells.” Pharmaceutical Research. 25(11):2555-66.
67. Hamdy S, Molavi O, Ma Z, Haddadi A, Ghotbi Z, El-Hasi S, Alshamsan A, Samuel J,
Lavasanifar A* (2008) “Co-delivery of cancer associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity”, Vaccine, 26:5046-5057.
68. Binkhathlan Z, Brocks DR, Lavasanifar A* (2008)“Development of a liquid
chromatography–mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma” Journal of Chromatography B, 869(1-2):31-7.
69. Molavi O, Ma Z, Hamdy S, Samuel J, Lai R, Lavasanifar A* (2008)“Synergistic anti-
tumor effects of CpG oligodeoxynucleotides and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model” Journal of Immunology and Cell Biology, 86(6):506-14.
70. Mahmud A, Xiong XB, Lavasanifar A* (2008) “Development of novel polymeric
micellar drug conjugates with hydrolysable core structure for doxorubicin delivery” European Journal of Pharmaceutics and Biopharmaceutics, 69:923-34. Ranked 36th out of 331 papers published in EJPB in 2008
71. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J* (2008)“Micelles of
poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization, stabilization and controlled delivery of curcumin” Journal of Biomedical Material Research A, 86(2):300-10.
LAVASANIFAR, AFSANEH Nov 2013
15
72. Molavi O, Ma Z, Lavasanifar A, Kwon GS, Samuel J* (2008)“Development of a polymeric micellar vehicle for the solubilization and controlled delivery of STAT3 inhibitor cucurbitacins” International Journal of Pharmaceutics, 347, 118–127.
73. Aliabadi HM, Romanick M, Desai S, Lavasanifar A* (2008) “Effect of buffer and
antioxidant on stability of a mercaptopurine suspension” American Journal of Health-System Pharmacy 1;65(5):441-7.
74. Mahmud A, Xiong X.B., Aliabadi HM, Lavasanifar A* (2007) “Polymeric micelles for
drug targeting” Journal of Drug Targeting, 15(9)553-584.
75. Açan Clements B, Incani V, Kucharski C, Ritchie B, Lavasanifar A, Uludağ H* (2007) “A comparative evaluation of poly-L-lysine-palmitic acid and Lipofectamine trade mark 2000 for plasmid delivery to bone marrow stromal cells” Biomaterials 28(31) 4693-4704.
76. Aliabadi HM, Brocks D, Mahdipoor P, Lavasanifar A* (2007) “A novel use of an in vitro
method to predict the in vivo stability of block copolymer based nano-containers.” Journal of Controlled Release. 122(1)63-67.
77. Aliabadi HM, El-Hasi S., Brocks DR, Lavasanifar A* (2008)“Polymeric micellar delivery
reduces nephrotoxicity of cyclosporine A” Journal of Pharmaceutical Sciences. 97(5):1916-1926.
78. Xiong XB, Mahmud, A, Uludag H, Lavasanifar A* (2007)“Conjugation of Arginine-
Glycine-Aspartic acid peptides to poly (ethylene-oxide)-b-poly(ε-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells” Biomacromolecules, 8(3):874-84. Top 20 most-assessed papers and Top 20 most-cited articles published in 2007 in Biomacromolecules
79. Haddadi A, Elamanchili, P, Lavasanifar A, Das S, Samuel J* (2007) “Delivery of
Rapamycin by PLGA Nanoparticles Increases its Suppressive Activity on Dendritic Cells” Journal of Biomedical Materials Research, 84A(4):885-898.
80. El-hasi S, Astaneh R, Lavasanifar A* (2007) “Solubilization of an amphiphilic drug by
poly(ethylene oxide)-block-poly(ester) micelles” European Journal of Pharmaceutics and Biopharmaceutics, 65(3) 406-413.
81. Ma Z, Shayeganpour A, Brocks DR, Lavasanifar A, Samuel J* (2007) "High-performance
liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin" Biomedical Chromatography, 21(5):546-552.
82. Incani V, Tunis E, Clements BA, Olson C, Kuncharski C, Somayaji V, Lavasanifar A,
Uludag H* (2007) “Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. Journal of Biomedical Materials Research, 81A(2):493-504.
LAVASANIFAR, AFSANEH Nov 2013
16
83. Aliabadi HM, Elhasi S, Mahmud A, Gulamhusein R, Mahdipour P, Lavasanifar A*
(2007) “Encapsulation of hydrophobic drugs in polymeric micelles through co-solvent evaporation: The effect of solvent composition on micellar properties and drug loading”. International Journal of Pharmaceutics 329(1-2)158-165.
84. Mahmud A, Xiong XB, Lavasanifar A* (2006) “Novel poly(ethylene oxide)-block-
poly(e-caprolactone) block copolymers with functional side groups on the polyester block for drug delivery” Macromolecules,39(26) 9419-9428.
85. Aliabadi HM, Spencer T, Mahdipour P, Lavasanifar A, Brocks DR, (2006) “Insights into
the effects of hyperlipidemia on cyclosporine A biodistribution and nephrotoxicity” AAPS Journal, 8(4) E672- E681.
86. Molavi O, Shayeganpour A, Somayaji V, Hamdy S, Brocks DR, Lavasanifar A. Kwon
GS. Samuel J* (2006) “A Sensitive and Specific Liquid Chromatography/Mass Spectrometry Method for Quantification of Cucurbitacin I (JSI-124) in Non-Biological Samples and Rat Plasma. Journal of Pharmacy and Pharmaceutical Sciences 9(2): 19-26.
87. Açan B, Bai J, Kucharski C, Farrell L, Lavasanifar A, Ritchie B, Ghahary A, Uludağ H*,
(2006) “RGD Conjugation to PEI Does Not Improve Transfection of Bone Marrow Cells”, Biomacromolecules, 7(5) 1381-1385.
88. Aliabadi HM and Lavasanifar A* (2006) “Polymeric micelles for drug delivery”, Expert
Opinion in Drug Delivery, 3(1):139-62.
89. Mahmud A and Lavasanifar A* (2005) “The effect of block copolymer structure on the internalization of poly(ethylene oxide)-block-poly(ε-caprolactone) micelles by human breast cancer cells”, Colloids & Surfaces B: Biointerfaces, 45(2) 82-89.
90. Aliabadi HM , Brocks DR, Lavasanifar A* (2005) “Polymeric micelles for the
solublization and delivery of Cyclosporine A: Pharmacokinetics and biodistribusion”, Biomaterials, 26(35) 7251-7259.
91. Aliabadi HM, Mahmud A, Sharifabadi AD, Lavasanifar A* (2005) “Micelles of methoxy
poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solublization and controlled delivery of cyclosporine A” Journal of Controlled release, 104; 301-311. (Top 10 most cited paper in Journal of Controlled Release in 2005)
92. Adams ML, Lavasanifar A, Kwon GS* (2003) “Amphiphilic block copolymers as self-
associating delivery agents” (minireview). Journal of Pharmaceutical Sciences, 92; 1343-1355. (Top 3 most cited paper in Journal of Pharmaceutical Sciences)
93. Lavasanifar A, Samuel J, Kwon GS* (2002) Poly(ethylene oxide)-block poly(L-amino
acid) micelles for drug delivery. Advanced Drug Delivery Reviews, 54; 169-190.
LAVASANIFAR, AFSANEH Nov 2013
17
94. Lavasanifar A, Samuel J, Sattari S, Kwon GS* (2002) Block copolymer micelles for the encapsulation and delivery of amphotericin B. Pharmaceutical Research, 19; 418-422.
95. Lavasanifar A, Samuel J, Kwon GS* (2002) The effect of fatty acid substitution on the in
vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide). Journal of Controlled Release, 79; 165-172.
96. Lavasanifar A, Samuel J, Kwon GS* (2001) “Micelles self assembled from poly(ethylene
oxide)-block-poly(N-hexyl stearate L-aspartamide) through a solvent evaporation method: Effect on solubilization and heamolytic activity of amphotericin B”, Journal of Controlled Release, 77; 155-160.
97. Lavasanifar A, Samuel J, Kwon GS* (2001) “The effect of alkyl core structure on
micellar properties in poly(ethylene oxide)-block-poly aspartic acid derivatives” Colloids & Surfaces B: Biointerfaces, 22; 115-126.
98. Lavasanifar A, Samuel J, Kwon GS* (2000) “Micelles of poly(ethylene oxide)-block-poly
(n-alkyl stearate) l-asparamide: synthetic analogs of lipoproteins for drug delivery”, Journal of Biomedical Materials Research, 52; 831-835.
99. Aramwit P, Yu B, Lavasanifar A, Samuel J, Kwon GS* (2000) “The effect of serum
albumin on aggregation state and toxicity of amphotericin B”, Journal of Pharmaceutical Sciences, 89 (12) 1589-1593.
100. Lavasanifar A*, Ghalandari R, Ataie Z, Zolfaghari ME, Mortazavi SA (1997)
“Microencapsulation of theophylline using ethylcellulose: In vitro drug release and kinetic modeling: Journal of Microencapsulation; 14 (1); 91 – 100.
Papers In Preparation/submitted:
1. M Rezazadeh; J Emami; F Hasanzadeh; A Mostafavi; H Sadeghi; M Minaiyan; M Rostami, A Lavasanifar “Development of novel chitosan-based polymeric micelles for targeted delivery of paclitaxel: Synthesis, characterization, in vitro cytotoxicity and in vivo pharmacokinetic evaluation”, Submitted.
2. Solymani H, Vakili MR, Zhang S., Lavasanifar A. “ABC tri block copolymer micelles as nano-reservoirs for drug solubilization and controlled delivery” In Preparation.
3. SM Garg, MR Vakili, A Lavasanifar, “The Effect of Pendent Group Chemistry on the Stability of Polymeric Micelles based on Functionalized Poly(ε-caprolactone)-block-poly(ethylene oxide): An In Vitro Study” Colloids and Surfaces B, In Preparation 4. N Safaei Nikouei, MR Vakili1, Markian S Bahniuk; Larry Unsworth, A Akbari, J Wu, A Lavasanifar* “Thermo-Reversible Hydrogels Based on Triblock Copolymers of Poly(ethylene glycol) and Carboxyl Functionalized Poly(<epsilon>-caprolactone): The
LAVASANIFAR, AFSANEH Nov 2013
18
Effect of Carboxyl Group Substitution on the Transition Temperature and Biocompatibility in Plasma" Acta Biomaterilia, submitted.
5. N Safaei Nikouei, and A Lavasanifar* “Triblock Copolymers Based on poly(ethylene glycol) and poly(a-benzyl carboxylate-co-carboxyl)-e-caprolatone for pH and Temperature Responsive Delivery of Macromolecules, In Preparation.
b. Patents/Patent applications 1. Lavasanifar A. and Safaiee Nekoie N. “Novel Biodegradable Thermoresponsive
Hydrogels” US patent application 61/254,478 filed in October 2009.
2. Lavasanifar, A., Xiong, XB “Novel ligand guided poly(ethylene oxide)-block-poly(ester micellar drug conjugates and nano-carriers for targted drug delivery.” PCT paenet application number PCT/CA2007/002298.
3. Lavasanifar A. and Mahmud A. “Novel poly(ethylene oxide)-block-poly(ester) block copolymers with reactive groups on the polyester block for drug delivery. US patent 8,309,515 (granted); Canada patent application No. 2646425 (notice of allowance issued); Eu patent No. EU7710774.6(granted); Japan patent application no. JP 2009-500678 (pending).
4. Lavasanifar A., and Kwon G.S., “Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs” US patent No. 11/569,719. Canada patent application No. 2,580,305.
5. Kwon, G.S., Samuel, J.S., and Lavasanifar, A. Methods and Compositions for Polyene Antibiotics with Reduced Toxicity. US Patent application No. 10/187,317, Filed on June 28, 2001, patent issued on March 10th, 2005.
c. Books and monographs 1. Xiong XB., and Lavasanifar A. “Amphiphilic Block Copolymer Based Nanocarriers for
Drug and Gene Delivery in Intracellular Delivery, Fundamentals and Applications. Springer, Editor: Ales Prokop, 2011; p251-290.
2. Xiong, XB., Uludag, H., Lavasanifar A. “Engineering of Amphiphilic Block Copolymers for Nanoscale Drug and Gene Delivery” in Nanotechnology in Drug Delivery” AAPS and Springer Science, Editor, Mel de Villiers, G.S. Kwon, Chapter 13, 2008 p385-422.
3. Xiong, XB., Aliabadi HM, Lavasanifar A.; “PEO-modified PLAA micelles for drug delivery” in “Nanotechnology and Cancer therapy”, CRC Press, Editor, Mansoor M Amiji, Chapter 18, 2007.
LAVASANIFAR, AFSANEH Nov 2013
19
d. Abstracts 1. Hoda Soleymani Abyaneh, Mohamadreza Vakili, Fanglin Zhan, Afsaneh Lavasanifar,
“Prepration of Micelle-forming block copolymers as nano-reservoirs for Controlled Drug Release” Annual meeting of CSPS, Montreal, June 2014.
2. Shyam M Garg, Mohamamdreza Vakili, Afsaneh Lavasanifar “Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates for delivery of STAT3 inhibitor JSI-124 to murine B16 melanoma” Annual meeting of the controlled release Society, Chicago, July 2014.
3. Qi Zhang, Mohammadreza Vakili, Afsaneh Lavasanifar “Novel Encapsulation of Arsenic
Trioxide into Polymeric Micelles” Annual meeting of the controlled release Society, Chicago, July 2014.
4. Shyam Garg, Mohammad Reza Vakili, Afsaneh Lavasanifar. The Effect of Core Structure
on the Physicochemical and Biological Stability of Polymeric Micelles based on Poly(ethylene Oxide) and Functionalized Poly(epsilon-caprolactone): an in vitro Study, Annual meeting of CSPS, Vancouver, June 2013.
5. Nazila Safaei Nikouei1, Mohammad Reza Vakili1 and Afsaneh Lavasanifar Development
of thermo-reversible gels based on tri block copolymers of poly(ethylene glycol) and functionalized poly(ε-caprolactone) for drug delivery, Annual meeting of CSPS, Vancouver, June 2013.
6. Hoda Soleymani, Mohammadreza Vakili, Afsaneh Lavasanifar. Role of Stereoregularity
in the Stability of Polymeric Micelles and their Release Profiles, Annual meeting of CSPS, Vancouver
7. Soleymani-Abyaneh H., Vakili M, and Lavasanifar A. “The effect of stereochemistry on
self-association of di and tri block copolymers based on poly(ethylene glycol), poly(lactide) and functionalized poly(e-caprolactone)” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.
8. Safaei Nikouei N, Vakili M, and Lavasanifar A “Development of thermoreversible gels
based on tri block copolymers f poly(ethylene glycol) and functionalized poly(ε-caprolactone) for drug delivery” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.
9. Garg S, Hamdy S, and Lavasanifar A “Polymeric micelles for the Delivery of Stat3
Inhibitor Cucurbitacin I to Tumor Suppressed Dendritic Cells: A Strategy to Enhance the Efficacy of Cancer Immunotherapy” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.
LAVASANIFAR, AFSANEH Nov 2013
20
10. Shahin M, Soudy R, Kaur K, and Lavasanifar A, “Decoration of Stealth Liposomal Doxorubicin Formulations with Engineered Peptides Targeting Breast Tumors: Evaluation of In Vitro and In Vivo Anti-cancer Activity” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.
11. Falamarzian A, Aliabadi HM, Marcoux, Y, Seubert JM, Uludag H, Lavasanifar A.,
“Effective Down-regulation of Signal Transducer and Activator of Transcription 3 (STAT3) by siRNA Delivery using Lipid Substituted Polyethyleneimines Leads to Cell Death in Wild Type and Doxoxrubicin Resistant Breast Cancer Cells” Annual meeting of the American Association of Pharmaceutical Scientists, Chicago, USA Oct 2012.
12. Soleymani-Abyaneh H., Vakili M, and Lavasanifar A. “Preparation of Micelle-forming
ABC Type Tri-Block Copolymers of poly(ethylene glycol), poly(lactide) and poly(α-benazylcarboxylate-ε-caprolactone): The effect of stereo-chemistry on micellar properties in drug delivery” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Toronto, June 2012.
13. Safaei Nikouei N, Vakili M, and Lavasanifar A “Tri Block Copolymers of Poly(ethylene
glycol) and functionalized poly(ε-caprolactone): Synthesis and characterization of their thermo-responsive sol-gel transition” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Toronto, June 2012.
14. Shahin M, Soudy R, Kaur K, and Lavasanifar A, “The effect of breast cancer cell
targeting peptide ligand density on the tumor selective delivery of doxorubicin by stealth liposomal formulations” ” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Toronto, June 2012.
15. Ahmed S, Mathews, A.S., Lavasanifar A, and Kaur K. “Engineering peptide-
nanoconjugates for breast cancer targeting”, Canadian Society for Chemists, May 2012, Calgary.
16. Shahin M, Soudy R, Kaur K, Lavasanifar A “Engineered peptides for breast tumor
targeted delivery of doxorubicin by stealth liposmal formulations: the effect of ligand density” 12th European Symposium on Controlled Drug Delivery, Netherland (April 4-6th), 2012.
17. Zhang, Q.; Xiong, X.-B.; Li, X-F.; Lavasanifar, A.; Le, X.C. Efficient polymeric micelle
encapsulation of p-aminophenylarsine oxide. The Joint 57th International Conference on Analytical Sciences and Spectroscopy and the 3rd Canada-China Analytical Chemistry Conference. Toronto, Canada, August 28-31, 2011. Abstract Book page 75.
18. Zhang, Q.; Xiong, X.-B.; Li, X-F.; Lavasanifar, A.; Le, X.C. Efficient polymeric micelle
encapsulation of p-aminophenylarsine oxide. Macgregor Research Day: Oral presentation. October 11, 2011.
LAVASANIFAR, AFSANEH Nov 2013
21
19. Shahin M, Soudy R, Kaur K, Lavasanifar A "Engineered peptides for active drug targeting by liposomal carriers of doxorubicin" 9th International Nanomedicine and Drug Delivery Symposium, Salt Lake City, Utah, USA (Oct 15-16), 2011.
20. Garg SM, Xiong XB, Hamdy S, Lavasanifar A Biocompatibility and Biodegradability of
Block Copolymers based on Poly(ethylene oxide) and Functionalized Poly(caprolactone) 9th International Nanomedicine and Drug Delivery Symposium, Salt Lake City, Utah, USA (Oct 15-16, 2011)
21. Safaei Nikouei N, Lavasanifar A, “Tri Block Copolymers of Poly (ethylene glycol) and
Functionalized Poly(ε-caprolactone): Synthesis and Characterization of their Thermo/pH Responsive Assembly” Annual meeting of the Canadian Society of Pharmaceutical Sciences, Montreal, May 2011.(winner of Cedarlane Award of Excellence for poster presentations)
22. Binkhathlan Z, Shayeganpour A, Brocks DR, Lavasanifar A, “Encapsulation of P-
glycoprotein inhibitors in polymeric micelles can reduce doxorubicin-free drug interactions” Annual meeting of the Canadian Chapter of Controlled Release Society, Montreal, May 2011.
23. Garg, S, Xiong, XB, Lavasanifar A, “The Effect of Core Structure on the
Biocompatibility and Biodegradability of Polymeric Micelles based on Functionalized Poly(ethylene Oxide)-block-poly(epsilon-caprolactone): an in vitro Study” International Conference on Materials for Advanced Technologies, July 2011, Singapore.
24. Garg, S, Xiong, XB, Lavasanifar A, “ The Stability and Biocompatibility of Crosslinked
Poly(ethylene oxide)-block-poly(epsilon-caprolactone) Micelles International Conference on Materials for Advanced Technologies, July 2011, Singapore
25. Lavasanifar A., Xiong XB, Ma, Z., Shahin, M., Mathews A.S., Ahmed, S., Kaur, K., "Targeted nanodelivery systems for improving response to cancer chemo and immonotherapy" 15th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA.
26. Garg S, Xiong XB, Lu C, Lavasanifar A, “ Application of Click Chemistry in the
Preparation of Novel Core Crosslinked Polymeric Micelles Based on Poly(ethylene oxide)-block-poly(ε-Caprolactone)” 15th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA.
27. Patel SK, Lavasanifar A, Choi P* “Prediction of the Solubility of Cucurbitacin Drugs in
Chemically Modified PEO-b-PCL Block Copolymers Using Moelcular Dynamics Simulation”, Canadian Chemical Engineering Conference, Saskatoon, SK, October 2010.
28. Xiong XB, Lavasanifar A*; “Tumor targeted polymeric micelles for co-delivery of
siRNA and anticancer drugs” Annual meeting of the Controlled Release Society,
LAVASANIFAR, AFSANEH Nov 2013
22
Portland, USA, July 2010 (winner of a travel award from the Canadian Chapter of the Controlled Release Society).
29. Alshamsan A, Hamdy S, Haddadi A, Samuel J, El-Kadi A, Uludag, H, Lavasanifar *.,
“Down-modulation of Stat3 in B16 melanoma by lipid modified PEI/sirna nano-complexes: Implications in cancer immunotherapy” Annual meeting of the Controlled Release Society, Portland, USA, July 2010(winner of a travel award from the Canadian Chapter of the Controlled Release Society).
30. Falamarzian A, Lavasanifar A* “Synthesis and characterization of novel PEG-PCL
based nano-carriers with acyl and cholesteryl structures for drug solubilization and delivery” Annual meeting of the Controlled Release Society, Portland, USA, July 2010.
31. Binkhathlan Z., ElHasi S., Lavasanifar A*, “Characterization of nano-structures formed
from assembly of poly(ethylene oxide)-b-poly(a-benzyl-e-caprolactone) in water” Annual meeting of the Controlled Release Society, Portland, USA, July 2010 (winner of a travel award from the Canadian Chapter of the Controlled Release Society).
32. Shahin M, Ahmad S, Kaur K, Lavasanifar A* “Synthesis and in vitro Evaluation of
Peptide Decorated Polymeric Micelles for Paclitaxel Delivery to Human Cancer Cells” Annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), June 2010, Vancouver, Canada. (winner of a travel award from CSPS).
33. Binkhathlan Z, ElHasi S, Brocks DR, Lavasanifar A* “Characterization of Nano-
carriers Formed from Self Assembly of Methoxy carboxylate-ε-caprolactone) for the Solubilization and in vivo Delivery of Valspodar” Annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), June 2010, Vancouver, Canada.
34. Xiong XB, Lavasanifar A* “Tumor Targeted Polymeric Micelles for Co-Delivery of siRNA and Anticancer Drugs: ANew Strategy for Chemo-Sensitization of Resistant Tumors” Annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), June 2010, Vancouver, Canada. (winner of a travel award from CSPS).
35. Kaur K*, Ahmed S, Mathews AS, Lavasanifar A “Cancer specific peptides from peptide arrays” Gordon research conference on Peptides, Chemistry & Biology of, Feb 28-March 5th, 2010, CA, USA.
36. Hamdy S, Alshamsan, A, Shayeganpour A, Haddadi A, Aliabadi HM, Lavasanifar A*,
“The immunosuppressive activity of polymeric micellar formulation of Cyclosporin A: in vitro and in vivo studies”. Annual meeting of AAPS, November 2009, Los Angeles.
37. Alshamsan A, Haddadi A, Hamdy S, Samuel J, Uludag H, El-Kadi AOS, Lavasanifar
A* “Targeting dendritic cells with PLGA nanoparticles of anti-STAT3 siRNA breaks
LAVASANIFAR, AFSANEH Nov 2013
23
cancer-mediated immune tolerance.” Annual meeting of AAPS, November 2009, Los Angeles.
38. Shahin M, Lavasanifar A* “Chemical tailoring of the core structure in poly(ethylene
Oxide)-b-poly(ε-caprolactone) micelles for paclitaxel solubilization and delivery” Annual meeting of AAPS, November 2009, Los Angeles.
39. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A* “A comparison between
pharmacokinetics of PSC 833 in the Cremophor EL formulation and polymeric micellar formulation.” Annual meeting of AAPS, November 2009, Los Angeles.
40. Falamarzian A, Kwon GS, Lavasanifar A * “Chemical tailoring of micelle forming
poly(ethylene oxide)-b-poly(ε-caprolactone) block copolymers: Effect on solubilization and hemolytic activity of Amphotericin B” Annual meeting of AAPS, November 2009, Los Angeles.
41. Safaei Nikouei N, Lin B, Sundararaj U, Lavasanifar A* “Development of Novel
Thermoresponsive Hydrogels for Drug Delivery Applications” Annual meeting of AAPS, November 2009, Los Angeles.
42. Molavi O, Mahmud A, Hamdy S, Hung R, Lai R, Samuel J, Lavasanifar A*
“Development of a poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticle formulation of STAT3 inhibitor JSI-124: Implication for cancer immunotherapy” Annual meeting of AAPS, November 2009, Los Angeles.
43. Haddadi A, Hamdy S, Ghotbi Z, Samuel J, Lavasanifar A* “Mannose receptor targeting
potentiates immunostimulatory effect of vaccine delivery systems” Annual meeting of AAPS, November 2009, Los Angeles.
44. Zahra Ghotbi, Azita Haddadi, Samar Hamdy, Ryan W. Hung, John Samuel and Afsaneh Lavasanifar. Dendritic cell (DC) targeting with mannan-adsorbed poly (D, L-lactide-co-glycolide) (PLGA) nanospheres. American Association of Pharmaceutical Scientists (AAPS), Los Angeles, November 2009.
45. Abbasi M, Incani V, Lavasanifar A, Uludag H* “siRNA delivery by lipid-modified
poly(l-lysine) for breast cancer therapy” Gene therapy conference, Sandiego, April 2009.
46. von Guggenberg E, Shahhosseini S, Koslowsky I, Lavasanifar A, Murray D, Mercer J*
“Evaluation of novel biodegradable vectors for improved cellular uptake of radiolabeled oligonucleotides” IRSR meeting in Edmonton, July 2009.
47. Koslowsky I, Shahhosseini S, von Guggenberg E, Murray D, Lavasanifar A, Mercer J*
“In vitro evaluation of a block copolymer as a potential transfection agent for [18F] labelled antisense oligonucleotides” 56th SNM annual meeting, Toronto, Canada, June 2009.
LAVASANIFAR, AFSANEH Nov 2013
24
48. Alshamsan A, Samuel J, Uludağ H , El-Kadi AOS, Lavasanifar A*, “Tumor Apoptosis after STAT3 Knockdown by Nano-Sized siRNA Complexes”, AFPC annual meeting, Halifax, Canada, June 2009 (Winner of the best student presentation for a travel award to AFPC conference).
49. Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A* “A Comparison between
Pharmacokinetics of Polymeric Micellar Formulation of Cyclosporine A and its more Hydrophobic Derivative PSC 833”, Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.
50. Alshamsan A, Uludağ H, Samuel J, Lavasanifar A*“RNAi-Based Nanomedicine for
Stat3 Knockdown in Melanoma Using Novel Poly(ethylenimine) Derivatives” Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.
51. Shahin M, Mahmud A, Lavasanifar A*“Novel Poly(ethylene oxide)-b-poly( -
caproactone-paclitaxel) conjugate micelles: Synthesis, characterization and antitumor activity.” Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.
52. Xiong XB, Uludağ H, Lavasanifar A*“Novel Biodegradable Amphiphilic Poly(ethylene
oxide)-block-polyesters with Grafted Polyamine as Supermolecular Nanocarrier for Efficient siRNA Delivery” Nanomedicine and drug delivery symposium, October 2008, Toronto, Canada.
53. Uludag H, Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A* “Delivery of
siRNA by lipid-modified poly(ethyleneimine): lipid substitution improves siRNA Stability in Serum” Proceedings of the 8th World Biomaterials Congress 2008, Amsterdam, Netherlands.
54. Mahmud A, Molavi O, Falamarzian A, Lavasanifar A*. “Chemical tailoring of the
hydrophobic block in self associating methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) with cholesteryl side chains for the solubilization of STAT-3 inhibitor Cucurbitacin I”. Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
55. Haddadi A, Ma Z, Hamdy S, Samuel J, Lavasanifar A* “Co-delivery of a new
generation of MUC1 antigens and Toll-like receptor ligands by biodegradable nanoparticles elicit strong T cell responses” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
56. Molavi O, Ma Z, Hamdy S, Samuel J, Lai R, Lavasanifar A* “Synergistic anti-tumor
effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
57. Shahin M, Ma Z, Ahmed S, Kaur K, Lavasanifar A* “Peptide decorated polymeric
micelles for selective intracellular drug delivery to metastatic breast cancer cells”
LAVASANIFAR, AFSANEH Nov 2013
25
Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
58. Safaei Nikouei N, Lin B, Sundararaj U, Lavasanifar A* “Preparation of
thermoresponsiv hydrogels for regional drug delivery” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
59. Hamdy S, Leila O, Ma Z, Haddadi A, Gobti Z, El Hasi S, Alshamsan A, Samuel J,
Lavasanifar A* “Therapy of established B16 melanoma tumors by vaccination with melanoma antigen co-encapsulated with adjuvant in PLGA nanoparticles” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
60. Ghotbi Z, Haddadi A, Hamdy S, Mahmud A, Samuel J, Lavasanifar A* “Development
of surface-anchored PLGA nanospheres with mannose-receptor ligands for targeting dendritic cells in cancer immunotherapy” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
61. Binkhathlan Z, El Hasi S, Brocks DR, Lavasanifar A* “Polymeric micelles for the
solubilization and delivery of P-glycoprotein inhibtor, PSC 833 (Valspodar)”. Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
62. Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludağ H* “Oleic-acid
and stearic-acid modification of polyethylenimine improved siRNA silencing effect in B16 melanoma”. Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Banff, Alberta, Canada.
63. Aliabadi HM, Mahdipour P, Brocks DR, Lavasanifar A* “The effect of drug loading
levels on the in vivo stability and pharmacokinetic profile of micellar nano-containers” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Montreal, Canada.
64. Xiong XB, Lavasanifar A* “Novel RGD4C-modified micellar drug conjugates for
chemosensitization of resistant tumors” Proceedings of the annual meeting of the Canadian Society of Pharmaceutical Scientists (CSPS), Montreal, Canada.
65. Aliabadi HM, Mahdipour P, Brocks DR, Lavasanifar A* “Novel use of an in vitro
method to predict the stability of block copolymer based nano-containers” The Proceedings of Thirteenth International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, USA.
66. Mahmud A, Xiong XB, Lavasanifar A* “Self-associating poly(ethylene oxide)-block-
poly( -caprolactone) copolymers with carboxyl, benzyl carboxylate and Doxorubicin
LAVASANIFAR, AFSANEH Nov 2013
26
side group: Novel micellar nano-containers and drug conjugates” The Proceedings of The Annual meeting of the Controlled Release Society, Long Beach, CA, USA, July 2007.
67. Xiong XB, Mahmud A, Lavasanifar A* “Novel Multifunctional Polymeric Micelles for
Targeted Drug Delivery” The Proceedings of the Annual meeting of the Controlled Release Society, Long Beach, CA, USA, July 2007.
68. Mahmud A, Xiong XB, Lavasanifar A* “Novel poly(ethylene oxide)-block-poly(ester)
block copolymers with aromatic or reactive side groups on the polyester block for drug delivery” Annual meeting of the American Association of Pharmaceutical Scientist (AAPS), San Antonio, Texas, October 2006.
69. Xiong XB., Mahmud A, Lavasanifar A* “RGD-modified poly(ethylene oxide)-poly(ε-caprolactone) micelles for enhanced intracellular drug delivery Annual meeting of the American Association of Pharmaceutical Scientist (AAPS), San Antonio, Texas, October 2006 .
70. Astaneh R, Lavasanifar A*. “Polymeric micelles as new vehicles for the intravenous
administration of amiodarone” Proceedings of the annual meeting of the Controlled Release Society, July 2006, Austria.
71. Haddadi A, Elamanchili P, Lavasanifar A, Samuel J* “Rapamycin Encapsulated in
PLGA Nanoparticles for Delivery to Dendritic Cells: Phenotypic and Functional Aspects, Proceedings of the annual meeting of the Controlled Release Society, July 2006, Austria.
72. Aliabadi HM, Mahdipour P, Brocks DR, Lavasanifar A* “Novel use of an in vitro
method to predict the stability of block copolymer based nano-containers” Annual meeting of CSPS, Toronto, Canada, June 2006.
73. Sarkhoshfard K, Ghahary A, Uludag H, Lavasanifar A* “Topical delivery of cox-1 and
cox-2 inhibitors by pluronic hydrogels for the prevention of hypertrophic scarring and fibrosis”, Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.
74. Aliabadi HM, Elhasi S, Brocks DR, Lavasanifar A* “Polymeric micellar delivery
reduces the nephrotoxicity of cyclosporine A” Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.
75. Elhasi S, Lavasanifar A* “Development of a freeze-thaw method for the preservation of
poly(ethylene)-block-poly(caprolactone) nanocarriers during storage” Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.
76. Xiong XB, Mahmud A, Uludag H, Lavasanifar A*“Preparation of RGD-conjugated
poly(ethylene oxide)-block-poly(ε-caprolactone) micelles for enhanced intracellular delivery of anticancer agents” Proceedings of the annual meeting of the Canadian Biomaterial Society, May 26-28, Calgary, AB, Canada.(Winner of the best poster presentation by a trainee).
LAVASANIFAR, AFSANEH Nov 2013
27
77. Aliabadi HM., Spencer T, Mahdipoor P, Lavasanifar A, Brocks DR* “Effect of
hyperlipidemia on cyclosporine A biodistribution” The annual meeting and exposition of American Association of Pharmaceutical Scientists (AAPS), 2005, Nashville, Tennessee, USA.
78. Aliabadi HM, Brocks DR, Lavasanifar A* “Polymeric micelles for the solublization and
delivery of cyclosporine A: Pharmacokinetics and biodistribution studies” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Toronto, Ontario, Canada, Journal of Pharmacy and Pharmaceutical Sciences 8(2) 2005.
79. Mahmud A, Lavasanifar A* “The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Toronto, Ontario, Canada, Journal of Pharmacy and Pharmaceutical Sciences 8(2) 2005.
80. El-Hasi S, Gholamhossein R, Aliabadi HM, Lavasanifar A* “Preparation of
monodispersed polymeric micellar formulations for efficient encapsulation of cyclosporine A through a co-solvent evaporation method” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Toronto, Ontario, Canada, Journal of Pharmacy and Pharmaceutical Sciences 8(2) 2005.
81. Açan B, Bai J, Kucharski C, Farrell L, Lavasanifar A, Ritchie B, Ghahary A, Uludağ, H*
“Cationic polymers as alternatives to viral gene delivery: RGD-conjugation to cationic polymers does not improve DNA delivery, Canadian Biomaterials Society meeting, Waterloo, 2005.
82. Aliabadi HM, Sharifabadi AD, Lavasanifar A* “Methoxy Poly(Ethylene Oxide)-
Poly( -Caprolactone) Copolymer Micelles for the Solubilization and Delivery of Cyclosporine A”. The 2004 Canada-Japan, Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada.
83. Mahmud A, Lavasanifar A* “The effect of block copolymer structure on the
internalization of Polymeric Micelles by Human Breast Cancer Cells”. The 2004 Canada-Japan Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada. (Winner of the best student presentation)
84. Haddadi A, Lavasanifar A, Samuel J “Rapamycin in PLGA Nanoparticles Efficiently
Inhibits Maturation of Dendritic Cells as Compared to Rapamycin in Solution” ”. The 2004 Canada-Japan Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada.
85. Acan B, Bai J, Kucharski C, Lavasanifar A, Uludag H. Bioaffinity of Peptide Conjugates
of Polyethyleneimine to Bone Marrow Stromal Cells. BIOMED-11 Meeting, Ankara, (September 2004)
86. Haddadi A, Lavasanifar A, Samuel J* “Rapamycin-loaded nanoparticles prepared by
LAVASANIFAR, AFSANEH Nov 2013
28
solvent evaporation technique: Drug loading and characterization.” Annual meeting of the Canadian Society of Pharmaceutical Scientist (CSPS), Vancouver, June 9-12., 2004, Journal of Phramacy and Pharmacutical Sciences 7(2)2004.
87. Mahmud A, Lavasanifar A* "Internalization of polymeric micelles by human breast
cancer cells" Presented in the NSERC nano-science poster presentation; Edmonton, AB (Nov 2003).
88. Sharifabadi AD, Lavasanifar A, Samuel J* “Polymeric Micellar Delivery to Dendritic
Cells” Presented in the NSERC nano-science poster presentation; Edmonton, AB (Nov 2003).
89. Lavasanifar A, Samuel J, Kwon GS* “Block Copolymer Micelles for Solubilization and
Delivery of Amphotericin B” Presented in the annual meeting of Canadian Association of Pharmaceutical Scientists, Banff, Alberta, Canada (June 2002).
90. Lavasanifar A, Samuel J, Kwon GS* “Block Copolymer Micelles for the Encapsulation
and Delivery of Amphotericin B” Presented in the annual meeting of the American Association of Pharmaceutical Scientists; Denver (Oct. 2001).
91. Lavasanifar A, Samuel J, Kwon GS; “Block Copolymer Micelles for the Solubilization
and Delivery of Amphotericin B” Presented in the Annual meeting of the Association of the Faculties of Pharmacy in Canada; Saskatoon (June 2000). (Winner of the best poster presentation by a graduate student for AFPC conference)
92. Lavasanifar A, Samuel J, Kwon GS*, “Block Copolymer Micelles for Solubilization
and Delivery of Amphotericin B” Proceedings of the annual meeting of the American Association of Pharmaceutical Scientists (AAPS); Neworleans (Nov. 1999). AAPS Pharm Sci Supplement Volume 3, Issue 3, 2000.
93. Lavasanifar A, Samuel J, Kwon GS*; “Block Copolymer Micelles for Drug Delivery:
Chemical Tailoring of the Alkyl Core Structure”. Annual meeting of the American Association of Pharmaceutical Scientists (AAPS) AAPS Pharm Sci Supplement, Volume 1, Issue 4, 1999.
94. Lavasanifar A, Samuel J, Kwon GS*; “Artificial Lipoproteins for the Delivery of
Amphotercin B”. Proceedings of the annual meeting of the Controlled Release Society, Boston, MA, USA, June 1999. Journal of Controlled Release, Issue 26 (pp 647-648) 1999.
95. Lavasanifar A, Samuel J, Kwon GS*; “Block Copolymer Micelles with Fatty Acid Core
Structure: Synthetic Analogs of Lipoproteins”. Presented in the annual meeting of the American Association of Pharmaceutical Scientists; San Francisco, Nov. 1998.
LAVASANIFAR, AFSANEH Nov 2013
29
e. Invited speaker
1. Lavasanifar A. “Nanotechnology for Improving Response to Cancer Chemo and Immunotherapy” 4th international conference on Pharmaceutics & Novel Drug Delivery Systems, San Ontonio, USA March 25th, 2014.
2. Lavasanifar A. “Nano-medicine for improved drug performance” College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, August 26, 2013.
3. Lavasanifar A, “Biodegradable polymers for drug and siRNA delivery: Super Medicine” Canadian Biomaterial Society, Student Chapter, Edmonton, Alberta, November 27, 2012.
4. Lavasanifar A, “Nanodelivery systems for cancer chemo and immunotherapy” School of Pharmacy, University of Toronto, Canada, August 2012.
5. Lavasanifar A, “Nanotechnology for cancer chemo and immunotherapy” School of Pharmacy, University of Waterloo, Canada, March 2012.
6. Lavasanifar A, “Novel Self-associating Biodegradable Polymers for Versatile Drug/Gene Delivery Applications” 2nd international conference on Pharmaceutics & Novel Drug Delivery Systems, Feb 20th, 2012, San Francisco, USA.
7. Lavasanifar A, “Nanotechnology for cancer chemo and immunotherapy” Small Talk, National Institute of Nanotechnology, University of Alberta, February 17th, 2012.
8. Lavasanifar A, “Biodegradable polymers for drug and siRNA delivery” Health and Medical Technology Seminar, Alberta Centre for Advanced MNT Products(acamp), December 1, 2011.
9. Lavasanifar A, “Nanomedicine: The medicine of future with improved therapeutic performance” 5th Iranian Controlled Release Conference, Mashhad, Iran, October 4-6th, 2011.
10. Lavasanifar A, “Nanomedicine: The medicine of future with improved therapeutic performance” College of Pharmacy, University of Houston, Houston, TX, USA, March 2nd, 2011.
11. Lavasanifar A, “Targeted nano-carriers for improving response to cancer chemo- and immunotherapy” 15th International Symposium on Recent Advances in Drug Delivery Systems, February 13-16, 2011, Salt Lake City, Utah, USA.
12. Lavasanifar A, “Targeted nano-therapeutics for improving response to cancer chemo- and immunotherapy” Annual meeting of the Canadian Society of Pharmaceutical Scientist, June 2010, Vancouver, Canada.
LAVASANIFAR, AFSANEH Nov 2013
30
13. Lavasanifar A, “Engineered polymeric micelles for overcoming drug resistance in cancer” Particles2010, May 2010, Orlando, Florida, USA.
14. Lavasanifar A, “Nanotechnology for improving drug performance”, CSPS Webinar, September 2009.
15. Lavasanifar A, “Nano-technology for drug solubilization and delivery” Annual meeting of the association of the Faculties of Pharmacy in Canada, May 2009, Halifax, Canada.
16. Lavasanifar A. “Drug targeting for controlled drug distribution” Annual meeting of the Canadian Society of Pharmaceutical Scientist” May 2008, Banff, Canada.
17. Lavasanifar A. “Engineered nano-delivery systems for chemo-sensitization of resistant tumors. Annual meeting of the Canadian Society of Pharmaceutical Scientist” May 30-June 2nd, 2007, Montreal, Canada.
18. Lavasanifar A. “Polymeric nano-assemblies for targeted drug delivery in cancer” 2006 International conference on Bio and Pharmaceutical Technology, December 18-21, San Diego, CA, USA.
19. Lavasanifar A., Aliabadi HM and Brocks, D. “Polymeric micelles for the tumor targeted delivery of P-gp inhibitors”, Particles 2006, May 13-16, 2006, Orlando, Florida, USA.
20. Lavasanifar A. “Nano-engineered polymeric micelles for drug delivery to resistant tumor” The 2004 Canada-Japan, Nanopharmaceutical Symposium, August 25-27, 2004, Banff, Alberta-Canada.
21. Lavasanifar A. “Block copolymer micelles: A new generation of colloidal delivery systems” School of Pharmacy, University of the Pacific, Stockton, USA, (2002).
22. Lavasanifar A. “Block copolymer micelles for the encapsulation and delivery of amphotericin B” School of Pharmacy, University of Manitoba, Canada, (2001).
f. Articles in professional journals without review committee 1. Hamdy S, Lavasanifar A, Samuel J* (2004) “Complexity and flexibility of dendritic cell
functions: possible manipulation for effective therapeutic strategy with two opposite outcomes (immunity and tolerance)” Bulletin of the faculty of Pharmacy, University of Cairo, 42 (2) 397-413.
2. Shafiee A*, Lavasanifar A, Pirooznia B, Mafakheri M, Kamal F; (1991); “New Derivatives of Nitroimidazoles: Synthesis, Antimicrobial and Antifungal Activity.” Journal of Science of I.R.I.; 1(3).
LAVASANIFAR, AFSANEH Nov 2013
31
E. SUPERVISION
a. Post Doctoral fellows (PDF), Research Associates (RA) and Laboratory Technicians Completed:
Name Position Period Project title Current position * Anahita Dehmoobed Sharifabadi
PDF 04/2002-09/2002
Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs
Community Pharmacist in Winnipeg
Anahita Dehmoobed Sharifabadi
PDF 09/2002-09/2004
Polymer based nano-carriers for dendritic cell targeting
Community Pharmacist in Winnipeg
*Zengshuan Ma
PDF 04/2007-04/2008
Development of new nano-formulations for delivery of curcumin and resveratrol
Research associate at the University of Alberta
*Ryan Hung PDF 07/2008-06/2009
Magnetic Resonance Imaging for In Vivo Tracking of Cancer Antigen-Specific T Lymphocytes
Medical Resident at the University of Alberta
*Azita Haddadi
PDF/RA 04/2007-07/2010
Ligand guided nanocarriers for targeted vaccine delivery
Assistant Professor, University of Saskatchwan
* Changuli Lu PDF 09/2008-04/2009
Development of core cross-linked micelles using click chemistry
PDF, University of Toronto
*Anooshirvan Shayeganpour
PDF 08/2008-07/2010
Tumor Targeted nano-delivery systems for improving response to chemotherapy in cancer
PDF/ Faculty of Medicine, U of Alberta
Annu Stella Mathews
PDF 09/2009-08/2010
Engineered peptides for cancer targeting
Research Scientist, Alberta Research Chemicals
* Xiaobing Xiong
PDF/RA 09/2005-08/2011
Development of novel multifunctional polymeric micelles for anticancer drug and siRNA delivery
Research Associate Wake Forest University Health Sciences, NC, USA
*Samar Hamdy
PDF 10/2008-08/2012
Ligand guided polymeric nanocarriers for targeted vaccine delivery in cancer
Community Pharmacist, Edmonton
*Elaine Moase Lab Tech. 02/2010-10/2011
Research Technologist, Merck Sorono, Edmonton
* Mostafa PDF 10/2012- Nanodelivery systems for Looking for employement
LAVASANIFAR, AFSANEH Nov 2013
32
Shahin 08/2013 detection of metastatic breast tumors
*Mohammadreza Vakili
PDF 06/2011-08/2013
Chemical Tailoring of PEO-poly(ester)s for drug delivery applications
*Mohammadreza Vakili
*Principle Supervisor
Significant awards received by the above trainees during their training period: Dr Ryan Hung AHFMR clinical fellowship
Dr Xiao-bing Xiong Best poster presentation in the 2006 annual meeting of the
Canadian Biomaterial Society, Calgary Best poster presentation in the 2006 Research Day, Faculty of Pharmacy, University of Alberta CSPS award for best poser abstract, CSPS annual meeting 2010, Vancouver, Canada.
Dr Samar Hamdy Best poster presentation in the 2009 Research Day, Faculty of Pharmacy, University of Alberta
Dr Mostafa Shahin The 2013 winner of the GattefosséCanada CSPS award in Lipid based drug delivery
Current:
Name Position Period Project title
*Mohammadreza Vakili
RA 09/2013 Chemical Tailoring of PEO-poly(ester)s for drug delivery applications
b. Graduate students: Completed:
Name Degree Period Thesis title Current position
Samuel Abraham
MSc 01/2002- 03/2006
Development of nanoparticulate delivery systems for IL-2
Community Pharmacist, Medicine Hat
* Hamidreza Montazeri Aliabadi
PhD 09/2002-09/2007
Polymeric micelles for the solubilization and delivery cyclosporine A as a model P-glycoprotein inhibitor
Research associate, Chemical and Material Engineering, University of Alberta
* Abdullah Mahmud
PhD 09/2002- 03/2008
Novel Polymeric Micellar Drug Conjugates and Nanocontainers for Drug Delivery Applications
Research Scientist, National cancer Institute, Maryland, USA
LAVASANIFAR, AFSANEH Nov 2013
33
* Reyhaneh Astaneh
Visiting PhD student
01/2005-11/2005
Polymer based nanocarriers for the solubilization and delivery of Amiodarone
Not aware
*# Samar Hamdy
PhD 09/2002-08/2008
Design of cancer vaccines Community Pharmacist, Edmonton
* Sara El-Hasi
MSc 01/2005-12/2008
Block copolymer based nano-carriers for drug delivery
Not aware
Basak Acan PhD 09/2003-01/2009
Gene Delivery to Bone Marrow Stromal Cells by Non-viral Carriers
NSERC post doctoral fellow, Ruger’s University
*# Leila Molavi
PhD 01/2004-09/2009
Delivery of STAT3 Inhibitor Cucurbitacins to Tumor by Polymeric Nano-Carriers: Implications in Cancer Chemo- and Immunotherapy
Assistant Professor, University of Tabriz, Iran
Sarthak Patal PhD 09/2006-12/2009
Molecular Dynamic Simulation for prediction of drug solubility in polymer based nanocarriers
Scientific Officer of a company in India
#Zahra Ghotbi
MSc 01/2004-01/2010
PLGA-based nanoparticles for targeting of dendritic cells in cancer immunotherapy and immunomonitoring
Taking PEBC exams
#Aws Alshamsan
PhD 09/2004-05/2010
Development of stat-3 targeting sirna nano-carriers for cancer therapy
Assistant Professor, King Saud University, Saudi Arabia
Vanessa Incani
PhD 09/2005-
10/2010
Improving Gene Delivery Efficiency by Lipid Modification of Cationic Polymers
Research Scientist, Innovotech Inc., Edmonton, Alberta
*Ziyad Binkhathalan
PhD 09/2005-07/2011
Development of block copolymer based nanocarriers for the solubilization and delivery of valspodar
Assistant Professor, King Saud University, Saudi Arabia
*Mostafa Shahin
PhD 01/2007- 09/2012
Development of polymer and lipid based nano-delivery systems for targeted cancer chemotherapy.
Community Pharmacist, Vancouver
*Arash Falamarzian
PhD 09/2007-07/2013
Lipid modification of polymeric nanocarriers for drug and siRNA delivery
CEO, Gol Daru, Iran
*Nazila PhD 09/2007- Biodegradable block copolymers Community Pharmacist,
LAVASANIFAR, AFSANEH Nov 2013
34
Safaei Nekouie
as Edmonton
* Principle supervisor # supervisor since 2007
Significant awards received by the above trainees during their training period: Hamidreza Montazeri Aliabadi Rx&D HFR/CIHR graduate scholarship
Queen Elizabeth II Graduate Scholarship
Abdullah Mahmud
Rx&D HFR/CIHR graduate scholarship
Best presentation by a research trainee, International Conference on MEMS, NANO and smart systems, Banff, Alberta
Samar Hamdy CIHR, Rx& D research fellowship.
Izaak Walton Killam Memorial scholarship (the most prestigious graduate scholarship at the University of Alberta).
Second best Poster Award (Dr. L. Chatten Award), Faculty of Pharmacy and Pharmaceutical Sciences Research day, 2007.
Basak Acan CIHR bone research training award
Rx&D/CIHR graduate scholarship
Queen Elizabeth II graduate scholarship
Leila Molavi Iranian Government Scholarship
Rx&D HFR/CIHR graduate scholarshipDr.
Prize for the best graduate poster presentation, Faculty of Pharmacy Research day, 2005 and 2008
AFPC Canadian Foundation for Pharmacy National Student Poster Award.
Aws Alshamsan Saudi Government Scholarship
Gattefossé Canada CSPS Award in Lipid-Based Drug Delivery (national wide), 2010, 13th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting.
LAVASANIFAR, AFSANEH Nov 2013
35
Vancouver, British Columbia, Canada
AFPC Travel Award for Best Graduate Student Poster, Faculty of Pharmacy and Pharmaceutical Sciences Research Day.
1st Place Wu Hong Memorial Poster Prize, Faculty of Pharmacy and Pharmaceutical Sciences Research Day, 2008.
Dr. Nojaim Memorial Award for Best Graduate Student Poster Presentation, Faculty of Pharmacy and Pharmaceutical Sciences Research Day, 2006.
Ziyad Binkhathlan Saudi government scholarship
Award for poster presentation in Faculty of Pharmacy research day in 2008 and 2009.
Travel ship award for poster presented in the annual meeting of the Controlled Release Society (CRS).
Mostafa Shahin
Egyptian government scholarship WCHRI trainee travel fund, Women and children’s health research institute (WCHRI), Canada. Oct 2012 WCHRI trainee travel fund, Women and children’s health research institute (WCHRI), Canada. June 2012 2nd best poster presentation (senior graduate students’ group) in the research and development day of the Faculty of Pharmacy and Pharmaceutical sciences, Faculty of Pharmacy, University of Alberta, Canada. 2011 ICR publication prize for article entitled "Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel.", published in Biomaterials. 2011 Aug;32(22):5123-33, Canadian Institute of Health Research (CIHR), Canada. 2011 CSPS annual meeting Travelship award, Controlled release Society, Canada 2010 BIOTEC annual meeting Travelship award, American Association of Pharmaceutical Sciences (AAPS), USA 2009 President‘s Doctoral prize of Distinction, University of Alberta, Canada. 2009 Frederick Banting and Charles Best Canada Graduate Scholarships - Doctoral Award, Canadian Institute of Health Research (CIHR), Canada 2009-2010 Residence Community Award (Outstanding Volunteer), Residence Services, University of Alberta, Edmonton, Canada. 2009
LAVASANIFAR, AFSANEH Nov 2013
36
Professional Development and Travel Grant, Graduate student association (GSA), University of Alberta, Canada. 2008 Shoppers drug mart graduate scholarship, Faculty of pharmacy and pharmaceutical sciences, University of Alberta 2008. Taiho/Alberta Endowed Fund Travel Assistant award, Faculty of pharmacy, university of Alberta 2008 Gattefossé Canada CSPS Award in Lipid-Based Drug Delivery 2013
Arash Falamarzian Best Overall Platform $800+AFPC Travel Award (Top‐ranked graduate student), Faculty of Pharmacy and Pharmaceutical sciences research day 2010 Alberta Cancer board graduate studentship award, Edmonton, Alberta (Sep 2010-Aug 2012) $20,000/year over two years Alberta Cancer board graduate studentship award, Edmonton, Alberta (Sep 2008-Aug 2010) $20,000/year over two years Dean’s special recruitment scholarship award, Faculty of Pharmacy and Pharmaceutical sciences, University of Alberta (Sep 2007-Aug 2008) $15,000
Nazila Safaei Nekouie Cedarlane Award of Excellence for poster presentations in the
annual meeting of CSPS in 2011
Current:
Name Degree Period Thesis title
*Shyam Garg
PhD 01/2010- Rational design and development of poly(ester) based nanocarriers for targeted cancer therapy
Qi Zhang PhD 09/2010- Development of new polymeric micellar formulations for tumor targeted delivery of arsenic trioxide derivatives
*Hoda Soleymani Abyaneh
PhD 09/2011- Development of polymeric micellar formulations for effective drug delivery to tumor micro-environment
Zhara Shire PhD 09/2012- Development of nanocarriers for synthetic lethal combination therapy of cancer
LAVASANIFAR, AFSANEH Nov 2013
37
*Igor Moura de Paiva
PhD 09/2014- Polymeric micelles for siRNA Delivery
* Principle supervisor
Significant awards received by the above trainees during their training period: Shyam Garg JN Tata Trust Endowment Scholarship 2009-2010
Alberta Cancer Foundation Graduate Studentship 2010 CIHR Institute of Cancer Research Travel Award Dr. John Samuel Memorial Graduate Scholarship Graduate Student Teaching Award 2012 Golden Key Research Grant 2011 Dr. Ronald Micetich Memorial Graduate Scholarship 2012 Dr. Ed Knaus Graduate Scholarship in Pharmaceutical Research 2012. Alberta Innovates Health Solutions graduate stundetship. Ranked 5th among 94 applications. April 2013.
Qi Zhang Medical Sciences Graduate Program Scholarship 2012.
Hoda Soleymani Abyaneh
Biochem Pharma Graduate Scholarship, University of Alberta, 2012. Graduate Research Assistantship Award, University of Alberta, 2012. Graduate Research Assistantship Award, University of Alberta, 2011. Mike Wolywik Graduate students ship (2013) WCHRI Graduate Studentship (2014)
c. Undergraduate students
Name Major Period Title of project Current position
Sabrina Rashid Science 05/2003- 09/2003
Development of nanoparticulate delivery systems for cancer immunotherapy
Not Aware
*Rashida Gholamhossein
Pharmacy 05/2004-09/2004
Polymeric micelles for the solubilization and delivery hydrophobic drugs
Community pharmacist
LAVASANIFAR, AFSANEH Nov 2013
38
*Homun Yee Science 09/2009- 03/2010
Chemical tailoring of micelle forming PEO-poly(ester) block copolymers
BSc Student, University of Alberta
* Shirley Zhang Pharmacy 06/2013-08/2013
Chemical tailoring of micelle forming PEO-poly(ester) block copolymers
Pharmacy student
*Amir Soleymai
Science 05/2014- Development of nanoparticles for STAT3-inhibtors
Chenzhen Zhang
Pharmacy-China
06/2014- Peptide modified polymeric micelles for drug targeting to metastic cancer.
*Principle supervisor Significant awards received by the above trainees during their training period: Rashida Gholamhossien - Best student presentation by an undergraduate student, Faculty of
Pharmacy Research Day, 2004
Homun Yee
- AHFMR summer studentship, 2009
d. Visiting researchers
Name Field Period Title of project Position
Dr Min Han Pharmacy 06/2012-11/2013
Mitocans for drug resistant tumors
College of Pharmaceutical Sciences, Zhejiang University, China
Dr Soheyla Honary
Pharmacy 01/2013-12/2013
Experimental design for optimization of polymeric micellar formulations.
Associate professor, Mazandaran University of Medical Sciences, Iran
Dr Alireza Shafatiee
Pharmacy 08/2014-07/2015
Stero-active polymers in drug delivery
Professor, Dr Beheshti University of Medical Sciences, Iran
e. Examining Committees:
LAVASANIFAR, AFSANEH Nov 2013
39
Candidate Degree and exam
Date Supervisor Faculty/ department
Gary Van D PhD, Defense 09/2003 D. Wishart Pharmacy Saidreza Harirfroush PhD, Candidacy 12/2003 F. Jamali Pharmacy Paras Nayer MSc, Defense 01/2005 J. Samuel Pharmacy Tina Grant PhD, Candidacy 07/2005 F. West Chemistry Saidreza Harirfroush PhD, Defense 12/2005 F. Jamali Pharmacy Welson Wang PhD, Candidacy 05/2006 M. Suresh Pharmacy Ali Rostami MSc, Defense 08/2006 F. West Chemistry Anooshiravan Shayganpour
PhD, Candidacy 12/2006 D. Brocks Pharmacy
Praveen Elemanchili PhD, Defense 03/2007 J. Samuel Pharmacy Basak Acan Clements PhD, Candidacy 05/2007 H. Uludag Pharmacy/Chemical
Engineering Arthur Okumo MSc, Defense 09/2007 R. Loebenberg Pharmacy Aws Alshamsan PhD, Candidacy 09/2007 A.El-Kadi Pharmacy Tina Grant PhD, Defense 11/2007 F. West Chemistry Sartak Patel PhD, candidacy 11/2007 P. Choi Chemical Engineering Weinan Hu PhD, defense 12/2007 H. Uludag Chemical Engineering Jenifer Hare PhD, Candidacy 12/2007 T. Allen Pharmacology Anooshiravan Shayganpour
PhD, defense 02/2008 D. Brocks Pharmacy
Reem Beleid MSc Defense 03/2008 K. Kaur Pharmacy Ingrid Koslowsky PhD, Candidacy 06/2008 J. Mercer Pharmacy Welson Wang PhD. Defense 08/2008 M. Suresh Pharmacy Sufeng Zhang Ph.D. Defense 09/2008 H. Uludag Chemical Engineering Sheema Afshar PhD, Candidacy 11/2008 T. Yeung Chemical Engineering Sahar Ahmed PhD, Candidacy 03/2009 K. Kaur Pharmacy Vannesa Incani PhD, Candidacy 06/2009 H. Uludag Pharmacy/Chemical
Engineering
M. Abbasi PhD, Candidacy 07/2009 H. Uludag Chemical Engineering
Ingrid Koslowsky PhD, Defense 06/2010 J. Mercer Pharmacy Gagandeep Kharaud MSc. Defense 08/2010 K. Kaur Pharmacy Jigar Patal PhD, Defense 10/2010 D. Brocks Pharmacy Vanessa Incani PhD, Defense 10/2010 H. Uludag Pharmacy Maryam Kabiri PhD, Candidacy 11/2010 L. Unsworth Chemical Engineering Jennifer Hare PhD, Defense 04/2011 T. Allen Pharmacology Krishna Chaitanya MSc, Defense 08/2011 K. Kaur Pharmacy Dharmendra Raghuwanshi
PhD, Candidacy 09/2011 K. Kaur Pharmacy
Dharmendra Raghuwanshi
PhD, Defense 07/2012 K. Kaur Pharmacy
LAVASANIFAR, AFSANEH Nov 2013
40
Krishna Chaitanya MSc, Defense 08/2012 K. Kaur Pharmacy Minashree Singh MSc, Defense 08/2012 K. Kaur Pharmacy Rawabi Qadhi MSc, Defense 10/2012 J. Seubert Pharmacy Arash Panahifar PhD, Candidacy 10/2012 M. Doschak Pharmacy Foroughalsadat Sanaee
PhD, Candidacy 11/2012 F. Jamali Pharmacy
Basak Shahin MSc, Defense 06/2013 H. Uludag Biomedical Engineering Maryam Kabiri PhD, Defense 03/2014 L. Unsworth Chemical Engineering Ali Akbari PhD, Candidacy 03/2014 Wu Agriculture and
Nutrition Forough Sanaiee PhD, Defense 03/2014 M. Jamali Pharmacy Arash Panahifar PhD, Defense 07/2014 M. Doschack Pharmacy Waheed Asghar PhD, Canidacy 09/2014 M Jamali Pharmacy
f. Supervisory committees:
Candidate Degree Supervisor Date
Paras Nayer MSc J Samuel 2002-2005 Mayowa Adelyde PhD M Suresh 2004-2007 Reem Belidad MSc K. Kaur 2005-2008 Arthur Okumu MSc R. Leobenberg 2006-2007
Dharmendra Raghuwanshi
PhD K. Kaur 2007-2012
Gagandeep Kharaud MSc K. Kaur 2008-2010 Jigar Patal PhD D. Brocks 2008-2010 Meysam Abbasi PhD H. Uludag 2009-2009 Rawabi Qahdi MSc J. Seubert 2009-2012 Maryam Kabiri PhD L. Unswarth 2010-present Hashem Etayash MSc K Kaur 2011-2012 Basak Shahin PhD H Uludag 2012-2013 Jieyu Zuo MSc R Loebenberg 2012-present Ali Akbari PhD Wu 2013-present Yougota MSc K Kaur 2014- Waheed Asghar PhD M Jamali 2014-
A. COMMITTEES a. At faculty and University level
III. SERVICE
LAVASANIFAR, AFSANEH Nov 2013
41
2003-2007 Research day committee (chair)
2004-2007 Seminar series committee (chair)
2004-2005 Appeals committee (member)
2004-2009 Graduate studies committee (member)
2006-2008 Curriculum committee (member)
2007-2009 Faculty Evaluation committee (member)
2008-2009 Admission committee (member)
2009-2011 Assessment committee (member)
2011-Present Faculty Development Seminar committee (chair)
2011-present Curriculum committee (member)
2011-present NMR committee (chair)
2011-2 Search committee for recruitment to a faculty position in drug delivery
2013 Faculty Retreat (co-Chair)
2013 Search committee for recruitment to a faculty position in drug delivery
2013-2014 co-Chair of Green and Gold Student Leadership and Professional Development Grant Committee
2014 Member of the Animal Care and Use Committee
2014 Chair of the Faculty of Pharmacy Committee restructure Task Force
b. At national/international level 2004 Technical committee of the Canada-Japan conference on MEMS,
NANO and smart systems, Banff, Alberta, Canada
2004 Representing NanoPharm group of the faculty of Pharmacy
2006 Organization of the poster competition in annual meeting of the Association of the Faculties of Pharmacy (AFPC) in June May 2006, Edmonton, Alberta
2006 Chair of Cancer Targeting Session in Particles 2006, May 13-16 Orlando, Florida
2006 Organization committee and chair of a session entitled “Polymeric micelles in cancer therapy” in “International conference on Bio and Pharmaceutical Technology”, December 18-21, 2006, San Diego.
2009 Organization committee and chair of a session entitled “Drug absorption and distribution” in annual CSPS meeting, May 22-25, 2009, Banff
2010 Organization committee and chair of a session entitled “New Directions in Clinical Applications of Delivery Systems for Cancer Treatment and
LAVASANIFAR, AFSANEH Nov 2013
42
Diagnosis” in annual CSPS meeting, June 2-6, 2010, Vancouver.
B. REVIEWING SERVICES
a. At faculty level 2002-2005 Contribution as a judge in compounding competition 2004-2006 Contribution as a judge for evaluation of the poster and podium
presentations in Research Day, Faculty of Pharmacy & Pharmaceutical Sciences
2006 and 2011 Contribution as a presenter in Career night for undergraduate students
b. At the University level 2011 Contribution as a reviewer in the internal review of CIHR grant
application by Dr Gary Eitzen entitled: “Identification of novel Rho GTPase inhibitors”
2012 Internal review of a CIHR grant Entitled “Phenylalkylhydrazine drugs and neuropsychiatric disorders” by Glen Baker
2013 Internal reviewer on PhD proposal for Ms. Valencia Serna Juliana for Biomedical Engineering Department
2014 Internal review of a CIHR program grant related to Dr Lai
c. At national/international level 2007-2010, 2014 Committee member for the pharmaceutical sciences panel of the CIHR
2006 External reviewer for Canadian Foundation for Innovation (CFI)
2007 External reviewer for The Welcome Trust, London, UK.
2008 External reviewer for Natural Science and Engineering Council of Canada (NSERC)
2008-2009 External reviewer for Saskatchewan Health Research Foundation 2009 Committee member for the National Cancer Institute of Canada
(NCIC). Panel G1 (Experimental Therapeutics, Medicinal Chemistry and Drug Development)
2009 External reviewer for Natural Resources and Applied Sciences (NRAS), Province of British Columbia
2009 Reviewer for the selection of best paper by graduate students at AFPC conference
2010 Reviewer for AFPC new investigator award in 2010
LAVASANIFAR, AFSANEH Nov 2013
43
2010 External Reviewer for NSERC discovery grant
2011 External reviewer for Danish Council for Independent Research/Natural Sciences
2011 Review of file for tenure promotion related to Dr Laired Forrest, Department of Pharmaceutical Chemistry, University of Kansas.
2012, 2013, 2014 Ad Hoc member of the GDD panel in NIH
2013 Reviewer for the promotion of Dr David Dubins to the Rank of Senior lecturer in Faculty of Pharmacy, University of Toronto
d. External examiner on PhD thesis 2011 Enzymatically active probiotics for topical and oral therapy” by
Mitchell Lawrence Jones, March 2011, From Department of Biomedical Engineering of McGill University, Supervisor Dr Sataya Prakash
2011 Development and characterization of intravesical mucoadhesive nanoparticulate formulations of paclitaxel and docetaxel for postoperative chemotherapy in non-muscle invasive bladder cancer” by Clement Mugabe, July 2011, from University of British Columbia, Supervisor Dr Helen Burt
2012 Novel Polysaccharide based polymers and nanoparticles for controlled delivery of drugs and imaging agents”, Faculty of Pharmacy, University of Toronto, August 2012. Supervisor Dr Shirley Wu.
2013 A multifunctional nanoparticle formulation for siRNA delivery targeting neurodegenerative disease and cancer, January 2013. Department Biomedical Engineering, Faculty of Medicine. McGill University, Supervisor Dr Satya Prakash,
2013 Development of Amino acid substituted Gemeni Surfactant based non-invasive Non-viral Gene Delivery Systems, August 2013, College of Pharmacy and Nutrition, University of Saskatchewan, Supervisor Dr Ildiko Badea.
C. CONSULTING SERVICES TO INDUSTRY
2002-2003 Development of water soluble formulations for intravenous administration of drugs with limited biological half-lives
2006 Novopharm, Assessing the stability of 6-Mercaptopurine suspensions
LAVASANIFAR, AFSANEH Nov 2013
44
2008 University of Alberta hospital, Assessing the stability of compounded thioguanine suspensions
2010-present Scientific Chief officer, Meros Polymers Inc.
D. TEACHING a. Undergraduate courses (Current)
Course Lecture hours-Lab hours Role
Pharmaceutics I (PHARM 331) 20 h-12h Contributor
Pharmaceutics II (PHARM 361) 8 h-24h Contributor-Coordinator
Pharm 341 2h Contributor
b. Graduate courses (Current)
Course Lecture hours Role
Advanced drug delivery systems (PHARM 610)
12h Contributor-coordinator
Directed project (Pharm 694) 20h Contributor
Biomaterial Science (CHE 582) 2 h Contributor
Top Related